Literature DB >> 3559648

Radiotherapy with curative intent: an option in selected patients relapsing after chemotherapy for advanced Hodgkin's disease.

M Roach, D S Kapp, S A Rosenberg, R T Hoppe.   

Abstract

Thirteen patients who had relapsed or failed to obtain a complete remission after combination chemotherapy for the treatment of advanced Hodgkin's disease were treated with subtotal or total lymphoid irradiation with curative intent. Twelve of the 13 patients achieved a complete response (CR). Five of the 12 CRs subsequently relapsed at 3, 9, 9, 12, and 19 months. One patient died of leukemia 11 months following radiotherapy. The actuarial relapse-free survival at 1 year was 60%, and six patients (50%) remain disease-free with a median follow-up of 34 months (range, 10 to 115 months) following the completion of radiotherapy. Patients who failed to obtain a CR to their initial chemotherapy, whose chemotherapy CR was of short duration, or who relapsed initially in extranodal sites, tended to have a worse outcome with radiotherapy. Patients who had long disease-free intervals after initial chemotherapy or relapsed only in nodal sites tended to do relatively well. Radiation therapy was well tolerated with no major toxicity. Potentially curative radiation therapy should be considered an option in the management of selected patients who relapse following combination chemotherapy for advanced Hodgkin's disease.

Entities:  

Mesh:

Year:  1987        PMID: 3559648     DOI: 10.1200/JCO.1987.5.4.550

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  4 in total

Review 1.  Changing role and decreasing size: current trends in radiotherapy for Hodgkin's disease.

Authors:  Joachim Yahalom
Journal:  Curr Oncol Rep       Date:  2002-09       Impact factor: 5.075

2.  An effective oral combination in advanced relapsed Hodgkin's disease prednisolone, etoposide, chlorambucil and CCNU.

Authors:  A L Lennard; P J Carey; G H Jackson; S J Proctor
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  Treatment patterns and disease outcomes for pediatric patients with refractory or recurrent Hodgkin lymphoma treated with curative-intent salvage radiotherapy.

Authors:  Christopher L Tinkle; Noelle L Williams; Huiyun Wu; Jianrong Wu; Sue C Kaste; Barry L Shulkin; Aimee C Talleur; Jamie E Flerlage; Melissa M Hudson; Monika L Metzger; Matthew J Krasin
Journal:  Radiother Oncol       Date:  2019-02-05       Impact factor: 6.280

4.  High dose melphalan, BCNU and etoposide with autologous bone marrow transplantation for Hodgkin's disease.

Authors:  G B Zulian; P Selby; S Milan; A Nandi; M Gore; G Forgeson; T J Perren; T J McElwain
Journal:  Br J Cancer       Date:  1989-04       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.